Workflow
摩根恒生生物科技交易型开放式指数证券投资基金
icon
Search documents
摩根恒生生物科技交易型开放式指数证券投资基金基金合同及招募说明书提示性公告
Xin Lang Cai Jing· 2026-01-22 20:14
2026年1月23日 特此公告。 摩根基金管理(中国)有限公司 摩根恒生生物科技交易型开放式指数证券投资基金的基金合同全文和招募说明书全文于2026年1月23日 在本公司网站(am.jpmorgan.com/cn)和中国证监会基金电子披露网站(http://eid.csrc.gov.cn/fund)披露, 供投资者查阅。如有疑问可拨打本公司客服电话(400-889-4888)咨询。 本基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资产,但不保证本基金一定盈利,也不 保证最低收益。请充分了解本基金的风险收益特征,审慎做出投资决定。 ...
摩根恒生生物科技交易型开放式指数证券投资基金基金份额发售公告
Group 1 - The fund being discussed is the Morgan Hang Seng Biotechnology Exchange-Traded Fund (ETF), which is a type of open-ended index securities investment fund [1][2][25]. - The fund's initial offering price is set at RMB 1.00 per share, and the subscription period is from January 26, 2026, to February 6, 2026 [3][5][29]. - The maximum fundraising limit for the fund is RMB 2 billion, and if this limit is reached, the fundraising will close early [5][6]. Group 2 - The fund is managed by JPMorgan Asset Management (China) Limited, with Guosen Securities Co., Ltd. serving as the custodian [2][26][55]. - The fund targets individual investors, institutional investors, qualified foreign investors, and other investors permitted by laws and regulations [2][23]. - The fund aims to passively track the performance of the Hang Seng Biotechnology Index, which reflects the overall performance of the largest 30 biotechnology companies listed in Hong Kong [9][10][24]. Group 3 - Investors can subscribe to the fund through online cash subscription or offline cash subscription methods [7][32]. - The fund's subscription fees are structured such that there are no fees for offline cash subscriptions, while online subscriptions may incur a fee of up to 0.3% [33][34]. - Investors must have a securities account to participate in the fund's subscription, specifically an A-share account or a fund account [37][38].